The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued for luspate...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado, Julio, Voltz, Caroline, Stain, Milena, Balkowiec-Iskra, Ewa, Mueller, Brigitte, Wernsperger, Johanna, Malinowska, Iwona, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288896/
https://www.ncbi.nlm.nih.gov/pubmed/34291195
http://dx.doi.org/10.1097/HS9.0000000000000616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288896/
https://www.ncbi.nlm.nih.gov/pubmed/34291195
http://dx.doi.org/10.1097/HS9.0000000000000616

Ejemplares similares